Dimensional Fund Advisors LP Makes New Investment in Eliem Therapeutics, Inc. (NASDAQ:ELYM)

Dimensional Fund Advisors LP acquired a new position in shares of Eliem Therapeutics, Inc. (NASDAQ:ELYM) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 12,560 shares of the company’s stock, valued at approximately $89,000.

Separately, Bank of New York Mellon Corp acquired a new position in Eliem Therapeutics during the second quarter worth $134,000. Institutional investors own 69.76% of the company’s stock.

Insider Activity

In other news, EVP Valerie Morisset sold 60,201 shares of the firm’s stock in a transaction on Friday, July 19th. The stock was sold at an average price of $7.21, for a total value of $434,049.21. Following the completion of the sale, the executive vice president now directly owns 100,322 shares in the company, valued at approximately $723,321.62. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Over the last ninety days, insiders sold 130,397 shares of company stock worth $997,902. 4.70% of the stock is owned by corporate insiders.

Eliem Therapeutics Stock Performance

Shares of NASDAQ:ELYM opened at $5.44 on Wednesday. Eliem Therapeutics, Inc. has a twelve month low of $2.35 and a twelve month high of $11.55. The firm has a market cap of $161.85 million, a PE ratio of -10.26 and a beta of -0.39. The business has a fifty day moving average of $6.41 and a 200-day moving average of $6.75.

Eliem Therapeutics (NASDAQ:ELYM) last announced its earnings results on Wednesday, August 14th. The company reported ($1.81) earnings per share for the quarter.

Eliem Therapeutics Company Profile

Eliem Therapeutics, Inc, a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.